Management of Diabetic induced Hyperlipidemia with Combined Therapy of Reducdyn and Metformin in Streptozotocin induced Diabetic Male Rats

• Published in: Research journal of pharmacy and technology Vol. 7; no. 9; pp. 1041 - 1045
• Main Authors: Nwauche, Kelechi ThankGod, Monago, C.C, Anacletus, F.C
• Format: Journal Article
• Language: English
• Published: A & V Publications 01.09.2014
• Subjects: diabetes; Hyperlipidemia; metformin; reducdyn; streptozotocin
• ISSN: 0974-3618; 0974-360X

Hyperlipidemia is the greatest risk factor of coronary heart disease. The present study was designed to investigate the complimentary effect of the co-administration of metformin and reducdyn in streptozotocin induced diabetic-hyperlipidemic male rats and a possible way of management of diabetic induced hyperlipidemia with the combination of these two drugs. Metformin was administered at a dose of 1.4mg/kg body weight per day for the period of the treatment. The fixed dose of metformin was co-administered differently with reducdyn at different doses of 0.25mg/kg and 0.5mg/kg body weight to group IV and V respectively for 3, 6 and 9 weeks. The statistical analysis was carried out using one way ANOVA followed by post hoc LSD multiple comparison on SPSS 19. Metformin, when administered alone and its co-administration with the different doses of reducdyn showed a significant decrease in the level of blood glucose concentration for 3, 6 and 9 weeks of treatment when compared with the diabetic control group. On induction of streptozotocin, the levels of serum total cholesterol, triglyceride and LDL were increased and HDL level decreased when compared with the normal control group. A remarkable decrease was observed in the levels of TC, TG and LDL and an increase in HDL level on the administration of metformin and its co-administration with reducdyn at different doses. It is important to observe that the co-administration of metformin 1.4mg/kg and reducdyn 0.25mg/kg body weight had a higher significant decrease in the levels of TC, TG and LDL and increase in HDL when compared with other treatment group for 3,6 and 9 weeks of treatment. This present study has proved that combination therapy using these two drugs can be used in the management of diabetic induced hyperlipidemia.